News

Find News

Filter articles

Applied Filters

Showing 981 to 990 of 1033 results

Bayer takes another swipe at Nexavar compulsory licence

India15-10-2013Legal developments

Bayer has appealed against the IPAB’s compulsory licence order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.

Teva wins Netherlands Copaxone case

Netherlands04-10-2013

Teva Pharmaceutical Industries has claimed victory in a patent revocation action brought by generic drug maker Mylan in the Hague over its blockbuster Copaxone drug, used in the treatment of multiple sclerosis.

FTC restricts Mylan’s acquisition of Agila amid antitrust fears

US02-10-2013

Mylan Inc will be forced to divest injectable generic drugs before it can complete a proposed $1.85 billion acquisition of Agila Specialities Global Pte Ltd and Agila Specialties Pvt Ltd after the FTC applied conditions to the deal.

India urged to improve its drugs patent policy

India, US30-09-2013

India’s drug patent policy has been slammed by US companies who are insisting that action be taken in order to improve trade relations.

Judge denies AstraZeneca’s bid to squash pay-for-delay challenge

US27-09-2013Legal developments

A federal judge has denied AstraZeneca’s motions to dismiss claims challenging its pay-for-delay deals with three generic pharmaceutical companies in connection to heartburn drug Nexium.

Teva holds on to Azilect exclusivity

US25-09-2013

The US District Court for the District of New Jersey has found in favour of Teva Pharmaceutical Industries Ltd in its patent infringement case with Mylan over Parkinson’s disease drug Azilect.

Ranbaxy receives notice for acne drug generic

US24-09-2013

Drug company Watson Laboratories (Actavis) has notified rival Ranbaxy Laboratories that it has applied to sell a generic version of anti-acne product Absorica in the US.

Austria becomes first country to ratify Unified Patent Court agreement

Austria, EU27-08-2013

Austria has become the first country in the EU to ratify consent to the Unified Patent Court.

Eli Lilly bids to stop generics cutting Alimta exclusivity

US23-08-2013

Eli Lilly has begun its defence of a patent covering lung cancer drug Alimta against generic companies including Teva, Barr Laboratories and APP Pharmaceuticals.

Horizon Pharma settles Duexis case with Par Pharmaceuticals

US22-08-2013Legal developments

US-based Horizon Pharma Inc agreed on August 22 to settle its patent dispute over arthritis drug Duexis with generic maker Par Pharmaceutical Companies.

Showing 981 to 990 of 1033 results

LSIPR